NEXICART-2 evaluates NXC-201 CAR-T in RR AL Amyloidosis, focusing on safety and efficacy outcomes. Results indicate rapid, deep hematologic responses with manageable toxicities, suggesting NXC-201 as a promising treatment.
Key Points:
- Research Problem/Question: Evaluate NXC-201 CAR-T in RR AL Amyloidosis.
- Methodology: Single-arm Phase 1b/2 trial with autologous BCMA-targeted CAR-T, lymphodepletion with fludarabine and cyclophosphamide.
- Key Findings: Rapid normalization of disease markers, deep responses with minimal toxicity.
- Significance/Impact: First U.S. CAR-T trial in RR AL Amyloidosis, potential new treatment avenue.
Conclusion:
NEXICART-2 demonstrates NXC-201's safety and efficacy in achieving rapid and deep hematologic responses in RR AL Amyloidosis, suggesting it as a promising therapeutic option.
Authors:
Heather Landau, Charlotte Hughes, Aaron Rosenberg, Mehrdad Abedi, Shahzad Raza, Jeffrey Zonder, Eugene Brailovski, Sergio Giralt, Sham Mailankody, Jae Park, Miguel-Angel Perales, Saad Usmani, David Marks, Raymond Comenzo, Sridevi Rajeeve, Jennifer Liu
Clinical Trial Registration Number: NCT06097832
DOI: 10.1200/JCO.2025.43.16_suppl.7508
Abstract#7508
